Initial Antibiotic Treatment Prior to Drainage for Subcutaneous Abscess
For simple, uncomplicated subcutaneous abscesses, incision and drainage (I&D) alone is the primary treatment, and antibiotics are NOT routinely required prior to drainage 1, 2.
When Antibiotics ARE Indicated Before/After Drainage
Antibiotic therapy should be added to I&D in the following specific situations 1, 2:
- Severe or extensive disease (multiple sites of infection)
- Rapid progression with associated cellulitis
- Signs of systemic illness (fever, tachycardia, sepsis)
- Immunosuppression or significant comorbidities
- Extremes of age (very young or elderly)
- Difficult-to-drain locations (face, hand, genitalia)
- Associated septic phlebitis
- Lack of response to I&D alone
Antibiotic Regimen Selection
For Outpatient Simple Abscesses (When Antibiotics Are Indicated)
Empirical coverage for CA-MRSA is recommended 1, 2. Choose ONE of the following oral options:
- Trimethoprim-sulfamethoxazole (TMP-SMX): 1-2 double-strength tablets twice daily (A-II evidence)
- Doxycycline or minocycline: 100 mg twice daily (A-II evidence)
- Avoid in children <8 years
- Clindamycin: 300-450 mg three times daily (A-II evidence)
- Best option if streptococcal coverage also needed
- Linezolid: 600 mg twice daily (A-II evidence)
- Expensive; reserve for resistant cases
Duration: 5-10 days, individualized based on clinical response 2.
For Hospitalized Patients with Complicated Abscesses
Empirical IV therapy for MRSA should be initiated 2:
- Vancomycin: 15-20 mg/kg/dose every 8-12 hours IV (A-I evidence)
- Linezolid: 600 mg IV/PO twice daily (A-I evidence)
- Daptomycin: 4 mg/kg IV once daily (A-I evidence)
- Clindamycin: 600 mg IV three times daily (A-III evidence)
Duration: 7-14 days based on clinical response 2.
Pediatric Considerations
For hospitalized children with complicated abscesses 2:
- Vancomycin is first-line (A-II evidence)
- Clindamycin 10-13 mg/kg/dose IV every 6-8 hours if clindamycin resistance <10% locally (A-II evidence)
- Linezolid 10 mg/kg/dose every 8 hours for children <12 years (A-II evidence)
- Avoid tetracyclines in children <8 years old
Critical Pitfalls to Avoid
Do NOT use rifampin as single agent or adjunctive therapy for skin/soft tissue infections 1, 2
Do NOT routinely give antibiotics for simple abscesses that can be adequately drained—this represents overtreatment 1, 2
Do NOT assume streptococcal coverage is needed for purulent abscesses—empirical therapy for β-hemolytic streptococci is likely unnecessary in purulent cellulitis 2
Cultures are recommended when antibiotics are used, to guide therapy if clinical response is inadequate 2
Evidence Quality Note
The IDSA guidelines 1, 2 provide A-II level evidence that I&D alone is adequate for simple abscesses. Recent trials 2 showed no significant difference in cure rates with TMP-SMX versus placebo for simple abscesses, though antibiotics may prevent short-term development of new lesions. The strongest evidence supports drainage first, antibiotics selectively based on the specific risk factors listed above.